Journal Responds to Controversy Over Embryo Gene-Editing Paper
By Jocelyn Kaiser,
Science Magazine
| 04. 28. 2015
Untitled Document
The journal that days ago published the first-ever paper on an attempt to genetically modify human embryos has come out in defense of its decision and rebuffed claims that the paper was not adequately peer reviewed.
The paper appeared online on 18 April in Protein & Cell, which is co-published by Springer and an affiliate of China’s Ministry of Education. Junjiu Huang and colleagues at Sun Yat-sen University in Guangzhou describe their efforts to use the CRISPR-Cas9 gene-editing technology to alter a gene in abnormal human embryos. Their gene-editing effort was not very successful and introduced many unintentional mutations.
The paper has touched off a furor from scientists and others who have called for a moratorium on any efforts to establish a pregnancy with such a genetically modified embryo. Many have deemed Huang’s experiment unethical, and Huang himself has reportedly said that the paper was rejected by Science and Nature in part for ethical reasons.
This week, Protein & Cell defended its decision to publish the paper. An editorial posted online on 28 April says the journal’s...
Related Articles
By Aisha Down, The Guardian | 11.10.2025
It has been an excellent year for neurotech, if you ignore the people funding it. In August, a tiny brain implant successfully decoded the inner speech of paralysis patients. In October, an eye implant restored sight to patients who had...
By Jessica Hamzelou, MIT Technology Review | 11.07.2025
This week, we heard that Tom Brady had his dog cloned. The former quarterback revealed that his Junie is actually a clone of Lua, a pit bull mix that died in 2023.
Brady’s announcement follows those of celebrities like Paris...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...
By Lauran Neergaard, AP News | 11.03.2025
WASHINGTON (AP) — The first clinical trial is getting underway to see if transplanting pig kidneys into people might really save lives.
United Therapeutics, a producer of gene-edited pig kidneys, announced Monday that the study’s initial transplant was performed successfully...